It does appear to indicate a point of disagreement which led to the changes to Board and Management. I guess the two potential outcomes for the FPP delivery platform was an earlier sale or out-licencing during the pre-clinical development phase or a push towards the clinic with potential phase 1 trials for FPP-cargoes.
Whatever the outcome, the science appears to be the big winner. The announcement appears to simply say lets get on with it.
Ann: Changes to Board and Management, page-35
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $886.5M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.0¢ | 17.5¢ | $508.8K | 2.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 118941 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 183634 | 2 |
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable